<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203124</url>
  </required_header>
  <id_info>
    <org_study_id>D0540C00016</org_study_id>
    <secondary_id>2010-022574-14</secondary_id>
    <nct_id>NCT01203124</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers</brief_title>
  <official_title>A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate how the dose of AZD8848 and the dosing frequency will affect the
      immunological/inflammatory response by measuring the production of biomarkers in blood and
      nasal lavage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes in blood and nasal lavage</measure>
    <time_frame>Samples collected pre-dose and 1 day after first dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes in blood and nasal lavage</measure>
    <time_frame>Samples collected pre-dose and 7 days after first dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes in blood and nasal lavage</measure>
    <time_frame>Samples collected pre-dose and 8 days after first dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes in blood and nasal lavage</measure>
    <time_frame>Samples collected pre-dose and 10 days after first dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CXCL 10 (IP-10) and mRNA expression of IFNα regulated genes in blood and nasal lavage</measure>
    <time_frame>Samples collected pre-dose and 12-14 days after first dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of intranasal administration of AZD8848 at different doses and dosing regimens</measure>
    <time_frame>During the 7 days dosing period and at four follow-up visits up to 11-13 months after the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given once daily on 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment once daily on 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8848</intervention_name>
    <description>The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women aged 18 to 55 years (inclusive). Women must be of
             non-childbearing potential or must have been stable on a highly effective
             contraceptive method for at least 3 months prior to Visit 1 and be willing to continue
             on the chosen contraceptive method, with additional use of a condom by male partners,
             until 3 months after last dose.

          -  Female subjects should have a negative pregnancy test at Visit 2 and date of last
             menstruation consistent of non-pregnancy

          -  Ability to metabolise AZD8848 (an in vitro screening assay will determine metabolic
             activity in a blood sample taken at Visit 1 using a pre-defined limit)

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically relevant abnormal findings in physical examination

          -  Structural abnormalities of the nose or nasal disorder symptomatic enough to cause
             significant nasal obstruction

          -  Ongoing pregnancy or lactation

          -  Abnormal immune function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leif T Eriksson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kuhn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1659&amp;filename=D0540C00016_Study_Synopsis.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Healthy</keyword>
  <keyword>Effect of different doses and dosing regimens of AZD8848 on biomarkers</keyword>
  <keyword>Effect different doses and dosing frequency of AZD8848 on biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

